Philip Serlin on IPO
From BioLineRx Ltd. (NASDAQ/TASE: BLRX) | Stock News Now · · Planet MicroCap
“We went public in Tel Aviv in 2007 in what was then the largest biotech IPO on the Tel Aviv Stock Exchange, raising $50 million, and in 2011 we listed on NASDAQ, which is now our main market with about 70% of our investor base US‑based.”
On , Philip Serlin, CEO at BioLineRx, spoke about IPO during BioLineRx Ltd. (NASDAQ/TASE: BLRX) | Stock News Now on Planet MicroCap.
About Philip Serlin
In a December 2016 interview, Philip Serlin, CEO of BioLineRx, discussed the company's business model and recent developments. He stated that BioLineRx, founded twelve years ago and based in Tel Aviv, focuses on in-licensing and developing therapeutic candidates from Israeli academic institutions and startups, primarily in oncology and immunology. Serlin noted that the company had brought 45 molecules into its pipeline over its history. Serlin highlighted a strategic collaboration with Novartis Pharma, signed about two years prior, in which Novartis invested $10 million and became the company's largest shareholder, owning approximately 10%. He said Novartis would fund about 75% of development costs under the agreement. Serlin also noted that BioLineRx went public on the Tel Aviv Stock Exchange in 2007 in what he described as the largest biotech IPO on that exchange, raising $50 million, and listed on NASDAQ in 2011, with about 70% of its investor base being US-based.